Gruczolakorak przewodowy trzustki: badanie fazy III leku INCB161734 i paclitaxel albumin-bound
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Tytuł w rejestrze: Comparing Radiotherapy Dose Strategies for Symptom Relief in Large Solid Tumors
Ośrodki prowadzące badanie w Polsce (1), alfabetycznie według miejscowości:
rekrutuje wkrótce nie rekrutuje lub brak danych
Kliknij kropkę, żeby zobaczyć ośrodki w mieście.
Więcej badań w tych miastach:
Stan rekrutacji pochodzi z rejestrów badań i może się zmienić szybciej, niż zaktualizuje go sponsor. Nasz doradca sprawdzi aktualny stan w wybranym ośrodku. Nie publikujemy nazwisk lekarzy ani ich danych kontaktowych.
Opis z rejestru (w języku angielskim):
This study will compare three ways of giving radiotherapy to relieve symptoms caused by a large solid tumor. Radiotherapy uses radiation to treat cancer. Researchers want to find out whether LATTICE radiotherapy, which gives a higher dose to small areas inside a tumor while treating the rest with a lower dose, improves symptom relief compared with two treatments that give a more even dose.
The study plans to enroll 426 adults. One tumor must be at least 7 centimeters across and have a volume of at least 100 cubic centimeters. It must cause a symptom rated at least 4 on a 0-to-10 severity scale. The symptom may be pain, pressure or fullness, difficulty breathing or swallowing, bleeding, or difficulty with an activity because of the tumor. All three study treatments must be technically suitable for the person.
Participants will be assigned by chance, with an equal chance of receiving one of three treatments:
* A total dose of 20 gray over five treatment sessions, given evenly to the treatment area. * A total dose of 25 gray over five sessions, given evenly to the treatment area. * LATTICE radiotherapy: 20 gray over five sessions to the treatment area, with selected small regions inside the tumor receiving a total dose of 66.7 gray during those same sessions.
Gray is a unit of radiation dose. The 66.7-gray dose is the total dose to the selected regions, not an additional 66.7 gray on top of 20 gray. Each treatment is given once a day on five consecutive working days. Participants and their treatment teams will know which treatment has been assigned.
Before assignment, each participant will choose the single tumor-related symptom they most want treatment to improve. The main assessment is about eight weeks after treatment. A response requires a decrease of at least 2 points in this symptom score, while the participant remains alive and has not needed unplanned local treatment of the study tumor through day 63 after the final session. Death or this additional local treatment counts as nonresponse, even if symptoms improved earlier. A missing symptom score in a participant who is alive and has not needed this treatment is handled separately in the analysis.
Researchers will also assess how quickly symptom relief starts, how long it lasts, quality of life, side effects, tumor changes on scans, further treatment, hospital use and survival. Medical care needed for comfort or safety will not be withheld. Some questionnaires can be completed by telephone if a participant cannot or does not wish to attend; telephone calls do not replace required examinations, blood tests or scans.
Hospital stays and days alive outside hospital are assessed during the first 90 days after assignment, including people who do not start or finish radiotherapy. Side effects are recorded before treatment and during follow-up; the acute treatment-related assessment extends to 90 days after the last radiotherapy session actually received. The first 15 participants assigned to LATTICE will receive additional treatment-plan and safety review within the randomized study. Participants will be followed for at least 12 months, where survival permits, with record-based or direct follow-up extending to 24 months when possible. A planned review of missing outcome information, without examining treatment effects, may increase enrollment to a maximum of 480 participants.
| Lek / interwencja | Rola | Postać, podanie |
|---|---|---|
| Homogeneous External-Beam Radiotherapy, 20 Gy in Five Fractions | Radioterapia | |
| Homogeneous External-Beam Radiotherapy, 25 Gy in Five Fractions | Radioterapia | |
| LATTICE Radiotherapy, 20 Gy With a Simultaneous Integrated Boost to 66.7 Gy in Five Fractions | Radioterapia |
Kryteria w języku angielskim, tak jak w rejestrze.
To główne kryteria z rejestru. Pełną listę i ostateczną decyzję o udziale ustala lekarz prowadzący badanie.
Zadzwoń, a nasz doradca ds. badań sprawdzi z Tobą wstępnie kryteria i pomoże skontaktować się z ośrodkiem. Kwalifikację zawsze przeprowadza lekarz w ośrodku. Udział w badaniu jest bezpłatny i dobrowolny.
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer
PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 11 listopada 2026.